You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東誠藥業(002675.SZ):收購米度生物部分股權並與關聯方向其增資
格隆匯 07-26 19:11

格隆匯 7 月 26日丨東誠藥業(002675.SZ)公佈,公司全資子公司南京江原安迪科正電子研究發展有限公司(“安迪科”或“受讓方”)以現金9665萬元收購世康控股有限公司(“世康控股”)持有的米度(南京)生物技術有限公司(度生物”)48.3084%股權(對應註冊資本949.37萬元);公司副總經理羅志剛以現金630萬元認購目標公司61.89萬元的新增註冊資本,佔其增資後總股本的2.9991%;南京江原安迪科正電子研究發展有限公司以現金370萬元認購目標公司36.35萬元的新增註冊資本,佔其增資後總股本的1.7614%

公司基於戰略規劃和經營發展的需要,收購目標公司部分股權,利用目標公司在分子影像技術中特色示蹤技術的優勢,精準定量、定性地確定新藥的靶向準確性及藥物的有效性,為公司創新藥物的決策確定及研發管線的戰略規劃奠定基礎;同時利用目標公司在核藥轉化方面的資源和經驗,為公司核藥在研新藥提供一站式CRO服務,進一步促進公司在研新藥轉化效率,加快新藥進入市場的速度本次投資有利於公司發揮協同效應,鞏固公司在核藥行業的市場地位,符合公司長期戰略發展,短期內不會對業績產生重要影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account